Osivax
Pioneering New Generation Of Vaccines

The number of firms active in vaccine manufacture, as well as the production processes they utilize, has changed dramatically since the dawn of the Covid-19 virus. Vaccine process development might provide distinct challenges for producers as most vaccinations are brand new and have minimal precedent or experience to draw on when predicting how people will react to them. Furthermore, when a medication is evaluated in people, promising preclinical outcomes in animal models are seldom replicated. In today's vaccine production climate, time to market and cost efficiency, in addition to seamless R&D and clinical trials, are critical concerns. Furthermore, sustaining a good manufacturing process necessitates scale-up and safety.

Osivax is a clinical-stage biotechnology business, intending to produce universal vaccine candidates designed to protect masses against viruses that mutate rapidly. The firm is focused on creating a game-changing pipeline of universal vaccines that exploit both arms of the immune system: enhanced T-cell immune responses created by its patented oligoDOM® technology and B-cell immune responses brought on by traditional vaccinations. Osivax is a pioneer in developing vaccines for influenza and is rapidly expanding to other areas such as Covid-19 and HPV. Founded in 2017, Osivax’s management team consists of seasoned multi-disciplinary experts that are dedicated to realizing the platform's potential and are backed by top scientific and clinical advisory boards. Since 2017, the Osivax team has progressed their universal influenza vaccine from preclinical to phase 2 trials, recruiting over 500 people and generating various proofs of concept using the platform's technology

Osivax's novel Proprietary Nanoparticle Technology - oligoDOM® is designed to trigger immense T-cell responses, including strong and sustained B-cell responses. The Nanoparticles in the technology self-assemble to present immunogenic structures of a specific virus in repetition to induce an innate immune response. Thanks to a special signal sequence targeting and activating immune system cells, oligoDOM® has been engineered to boost the T-cell immunological response to the native antigen.

By converting a tiny, non-immunogenic native antigen into a big nanoparticle that is easily identified by the immune system and exposing numerous copies of the original antigen, oligoDOM®, like other self-assembling nanoparticle technologies, elicits a robust B-cell response. The oligoDOM® technology platform is very adaptable since it can be employed with a variety of antigens as well as within a variety of vaccination technologies, such as recombinant proteins or mRNA technology, resulting in multiple value creation potential.

The company announced positive findings from its Phase 2a clinical study with OVX836, a broad-spectrum influenza vaccine candidate created utilizing the company's patented oligoDOM® nanoparticle technology platform, in December 2021. OVX836, unlike traditional vaccines that target highly modifying surface proteins and must be updated to meet seasonal influenza strains, targets the interior nucleoprotein (NP), a highly conserved antigen that is significantly less vulnerable to changes and hence provides universal protection.

Current seasonal flu vaccinations are only partially effective as they target strain-specific surface antigens, which mutate at a rapid pace and consequently vary seasonally. A universal vaccination offers the critical possibility to give broad coverage across all seasonal and pandemic strains, which is sorely required. In preclinical testing, Osivax's lead candidate demonstrated strong and long-lasting systemic and local immune responses. In a GLP toxicological investigation, it demonstrated high activity against both A and B strain flu viruses in vivo, as well as a favorable safety profile.